CAN-2409 Boosts DFS in Localized Prostate Cancer with EBRT
Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response rates in intermediate-to-high-risk prostate cancer.
Related Articles
D-VRd Improves Responses & Survival in Transplant-Ineligible NDMM
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
FINER Trial: Ipatasertib Combo Extends PFS in ER+/HER2- Breast Cancer
Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative metastatic breast cancer patients post-CDK4/6 therapy.
Integrated Biomarkers Boost RCC Response Prediction
David A. Braun, MD, PhD, reveals how integrating tumor and circulating biomarkers enhances treatment response predictions in advanced renal cell carcinoma.
ShorTrip: SCRT & FOLFOX/FOLFOXIRI for Locally Advanced Rectal Cancer
The ShorTrip trial found that short-course radiotherapy followed by FOLFOX and FOLFOXIRI improved pathological response rates in locally advanced rectal cancer.
Relacorilant Improves PFS/OS in Platinum-Resistant Ovarian Cancer
Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.
Neoadjuvant Nivolumab & Chemo Improves NSCLC Overall Survival
Neoadjuvant nivolumab plus chemotherapy significantly improves overall survival in resectable non-small cell lung cancer, marking a treatment breakthrough.
Zipalertinib: Enhanced Accessibility & Quality of Life in NSCLC
Helena Yu, MD, discusses the importance of zipalertinib’s oral administration route for patients with EGFRm non–small cell lung cancer.
BNT327/Chemo Shows Durable Responses in Mesothelioma
A novel bispecific antibody, BNT327/PM8002, shows promising efficacy in treating unresectable mesothelioma, combining well with chemotherapy for durable responses.
Epcoritamab Yields Durable Remissions in R/R LBCL at 2 Years
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
TTFields Show Significant Survival Benefit in Pancreatic Cancer
Vincent Picozzi, MD, discusses findings from the phase 3 trial PANOVA-3 of TTFields with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.